Welcome to our dedicated page for Exelixis SEC filings (Ticker: EXEL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Exelixis Inc. filings document regulatory disclosures for a Nasdaq-listed oncology company with common stock trading under EXEL. Recent 8-K reports furnish results of operations, financial-condition updates, corporate updates tied to the cabozantinib franchise and pipeline activity, and board-authorized common stock repurchase programs.
Proxy and governance filings cover director election matters, executive compensation, equity awards and shareholder voting materials. Other current reports document officer appointments, departures and related compensatory arrangements, connecting leadership changes to the company's research, development, legal and corporate functions.
Oliver Bob reported acquisition or exercise transactions in this Form 4 filing.
EXELIXIS, INC. director Oliver Bob received a grant of 8,367 shares of Common Stock in the form of restricted stock units as compensation. The RSUs were granted at no cash cost and will vest in full on May 27, 2027, if he remains in continuous service. After this award, he directly holds 29,487 shares, including 17,455 shares that will be issued upon vesting of existing RSUs.
WYSZOMIERSKI JACK L reported acquisition or exercise transactions in this Form 4 filing.
Exelixis, Inc. director Jack L. Wyszomierski received a grant of 8,367 restricted stock units, each equal to one share of common stock, under the 2017 Equity Incentive Plan. The RSUs vest in full on May 27, 2027, subject to continuous service, bringing his reported holdings to 288,309 shares.
POSTE GEORGE reported acquisition or exercise transactions in this Form 4 filing.
EXELIXIS, INC. director George Poste received a grant of 8,367 restricted stock units, each equal to one share of common stock and granted at no cost, under the company’s 2017 Equity Incentive Plan. The RSUs vest in full on May 27, 2027, subject to his continuous service. After this award, he directly beneficially owns 127,199 shares of common stock, including the unvested RSUs.
EXELIXIS, INC. director David Edward Johnson reported receiving an option grant covering 19,133 shares of common stock. The option has an exercise price of $50.03 per share, is exercisable immediately subject to repurchase provisions, and expires on May 26, 2033. It will vest in full on the first anniversary of the grant date, conditioned on Mr. Johnson’s continuous service. After this award, he holds options for 19,133 shares. Footnotes state the securities are deemed held for the benefit of Caligan Partners Master Fund LP and certain managed accounts of Caligan Partners LP, and may be transferred to those entities after vesting.
Exelixis, Inc. reported the results of its 2026 annual stockholder meeting. Stockholders approved an amended and restated 2017 Equity Incentive Plan, which became effective immediately upon approval. All 11 director nominees were elected to serve until the next annual meeting in 2027.
Stockholders ratified Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending January 1, 2027. They also approved, on an advisory basis, the compensation of Exelixis’ named executive officers, confirming support for the company’s current governance and compensation framework.
EXELIXIS, INC. executive Dana Aftab, EVP of Research and Development, reported an open-market sale of Common Stock. On May 26, 2026, Aftab sold 43,451 shares of Exelixis common stock at $50.35 per share.
After this transaction, Aftab directly holds 594,741 shares of common stock. In addition, a separate entry shows 5,835 shares held indirectly through the Exelixis 401(k) Plan. Footnotes also note 405,966 shares that may be issued upon vesting of restricted stock units and performance-based restricted stock units, each representing the right to receive one share of common stock.
EXEL filing a Form 144 that lists proposed sales of common stock by an executive/affiliate. The excerpt shows multiple lots tied to restricted stock vesting, performance stock units, and an employee stock purchase plan with dated entries ranging from 04/30/2024 to 05/15/2025.
The filing lists several share lots (e.g., 6,223 shares, 6,246 shares, 7,794 shares) associated with issuer-issued compensation and proposed resale; proceeds treatment and aggregate offer total are not stated in the provided excerpt.
Exelixis, Inc. executive Patrick J. Haley reported an open‑market sale of 32,110 shares of Common Stock. The shares were sold at a weighted average price of $49.81 per share, with individual trades ranging from $49.80 to $49.89.
After this transaction, Haley directly holds 357,638 shares of Exelixis common stock. Footnote disclosure states that this figure includes 356,992 shares that will be issued upon vesting of restricted stock units and a performance-based restricted stock unit award, each convertible into one share of common stock.
EXEL reported Rule 144 transactions for shares of Common Stock related to restricted stock vesting under a registered plan. The filing lists a total of 32,110 shares across multiple vesting events dated 05/15/2026, with the filing recorded on 05/20/2026.
The entries identify the issuer as the reporting seller and itemize vesting lots of 8,683, 7,779, 5,859 and 9,789 shares. The filing describes these as issuer-held restricted stock vesting under a registered plan.
EXELIXIS, INC. President and CEO Michael Morrissey reported non-market share dispositions consisting of tax withholding and bona fide gifts of common stock. On May 15, 2026, 128,497 shares were withheld at $51.10 per share to satisfy taxes tied to the vesting of restricted stock units awarded between 2022 and 2025.
On May 18, 2026, he made two bona fide gifts of 124,047 shares each, one from direct holdings and one involving the Morrissey Family Living Trust, for a total of 248,094 gifted shares at no consideration. After these transactions, filings show 1,362,008 shares associated with RSUs and performance-based awards, 2,004,327 shares held by the family trust, and 17,728 shares in the company 401(k) plan.